Follow-On Biologics Guidance Delay Lauded By Senate Health Cmte. Staffer

FDA should not issue a guidance on follow-on biologics until after Congress has established a regulatory pathway, Senate Health Committee Counsel Steve Irizarry said at an American Conference Institute meeting in New York June 25